It highlights how proven digital innovation can be replicated to curb the spread of COVID-19 in Africa. It also estimates investment required to implement such high impact solutions.
факты о легких и туберкулезе - информационная брошюра ; первая часть
(Туберкулез с множественной лекарственной устойчивостью ; вторая часть)
Accessed on September 2019
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte
...
d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
A tutorial for healthcare professionals
Strengthening health-system emergency preparedness.
- Conference summary report
Infographic/Map on Cholera and Diphteria cases in Yemen
An update from the EU Early Warning System
EMCDDA Insights - 11
Accessed: 14.03.2019
The European Commission allocated an emergency aid package of €3.5 million on 19/03. The funding will be used to provide logistical support to reach affected people, emergency shelter, hygiene, sanitation, and health care. Out of the aid package,
...
based on needs, €2 million will be provided in Mozambique, €1 million in Malawi and €0.5 million in Zimbabwe.
more
Harm reduction: evidence, impacts and challenges
-10-